nodes	percent_of_prediction	percent_of_DWPC	metapath
Norfloxacin—CYP1A1—Clobetasol propionate—psoriasis	0.109	0.144	CbGbCtD
Norfloxacin—CYP2A6—Methoxsalen—psoriasis	0.0671	0.0887	CbGbCtD
Norfloxacin—CYP1A1—Methoxsalen—psoriasis	0.0573	0.0758	CbGbCtD
Norfloxacin—CYP3A5—Beclomethasone—psoriasis	0.0496	0.0656	CbGbCtD
Norfloxacin—CYP1A2—Clobetasol propionate—psoriasis	0.0487	0.0645	CbGbCtD
Norfloxacin—CYP1A1—Cholecalciferol—psoriasis	0.038	0.0502	CbGbCtD
Norfloxacin—CYP2A6—Prednisolone—psoriasis	0.0326	0.0431	CbGbCtD
Norfloxacin—CYP1A2—Methoxsalen—psoriasis	0.0256	0.0339	CbGbCtD
Norfloxacin—SLC22A6—Cyclosporine—psoriasis	0.0219	0.0289	CbGbCtD
Norfloxacin—CYP3A7—Hydrocortisone—psoriasis	0.0211	0.028	CbGbCtD
Norfloxacin—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0211	0.028	CbGbCtD
Norfloxacin—CYP3A7—Cyclosporine—psoriasis	0.02	0.0264	CbGbCtD
Norfloxacin—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.02	0.0264	CbGbCtD
Norfloxacin—CYP3A5—Mycophenolate mofetil—psoriasis	0.0198	0.0261	CbGbCtD
Norfloxacin—CYP2A6—Dexamethasone—psoriasis	0.0192	0.0254	CbGbCtD
Norfloxacin—CYP3A4—Calcitriol—psoriasis	0.0172	0.0228	CbGbCtD
Norfloxacin—CYP1A1—Dexamethasone—psoriasis	0.0164	0.0217	CbGbCtD
Norfloxacin—CYP3A5—Hydrocortisone—psoriasis	0.0159	0.021	CbGbCtD
Norfloxacin—CYP3A5—Cyclosporine—psoriasis	0.015	0.0198	CbGbCtD
Norfloxacin—CYP3A4—Methoxsalen—psoriasis	0.0134	0.0177	CbGbCtD
Norfloxacin—CYP3A7—Dexamethasone—psoriasis	0.0131	0.0174	CbGbCtD
Norfloxacin—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0131	0.0174	CbGbCtD
Norfloxacin—SLC22A6—Methotrexate—psoriasis	0.0116	0.0153	CbGbCtD
Norfloxacin—CYP3A5—Dexamethasone—psoriasis	0.00986	0.013	CbGbCtD
Norfloxacin—CYP3A4—Cholecalciferol—psoriasis	0.00889	0.0118	CbGbCtD
Norfloxacin—CYP3A4—Mycophenolate mofetil—psoriasis	0.0077	0.0102	CbGbCtD
Norfloxacin—CYP3A4—Triamcinolone—psoriasis	0.0077	0.0102	CbGbCtD
Norfloxacin—CYP3A4—Betamethasone—psoriasis	0.00661	0.00874	CbGbCtD
Norfloxacin—CYP3A4—Prednisolone—psoriasis	0.00652	0.00863	CbGbCtD
Norfloxacin—CYP3A4—Hydrocortisone—psoriasis	0.00618	0.00818	CbGbCtD
Norfloxacin—CYP3A4—Prednisone—psoriasis	0.00616	0.00815	CbGbCtD
Norfloxacin—CYP3A4—Cyclosporine—psoriasis	0.00584	0.00772	CbGbCtD
Norfloxacin—CYP3A4—Dexamethasone—psoriasis	0.00384	0.00509	CbGbCtD
Norfloxacin—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.0016	0.0812	CbGpPWpGaD
Norfloxacin—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.00108	0.0549	CbGpPWpGaD
Norfloxacin—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.000993	0.0504	CbGpPWpGaD
Norfloxacin—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000783	0.0397	CbGpPWpGaD
Norfloxacin—CYP1A1—Xenobiotics—CYP2S1—psoriasis	0.00074	0.0375	CbGpPWpGaD
Norfloxacin—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000472	0.0239	CbGpPWpGaD
Norfloxacin—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00045	0.0228	CbGpPWpGaD
Norfloxacin—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000444	0.0225	CbGpPWpGaD
Norfloxacin—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000413	0.0209	CbGpPWpGaD
Norfloxacin—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000407	0.0206	CbGpPWpGaD
Norfloxacin—TOP2A—G0 and Early G1—PCNA—psoriasis	0.000389	0.0197	CbGpPWpGaD
Norfloxacin—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000365	0.0185	CbGpPWpGaD
Norfloxacin—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000364	0.0185	CbGpPWpGaD
Norfloxacin—TOP2A—Methyltestosterone—Hydrocortisone—psoriasis	0.000345	0.258	CbGdCrCtD
Norfloxacin—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000334	0.0169	CbGpPWpGaD
Norfloxacin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000325	0.0165	CbGpPWpGaD
Norfloxacin—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000321	0.0163	CbGpPWpGaD
Norfloxacin—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000307	0.0156	CbGpPWpGaD
Norfloxacin—CYP1A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000303	0.0154	CbGpPWpGaD
Norfloxacin—TOP2A—Methyltestosterone—Prednisone—psoriasis	0.000297	0.222	CbGdCrCtD
Norfloxacin—TOP2A—Methyltestosterone—Prednisolone—psoriasis	0.00029	0.217	CbGdCrCtD
Norfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—VDR—psoriasis	0.000264	0.0134	CbGpPWpGaD
Norfloxacin—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000264	0.0134	CbGpPWpGaD
Norfloxacin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000258	0.0131	CbGpPWpGaD
Norfloxacin—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000249	0.0126	CbGpPWpGaD
Norfloxacin—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000249	0.0126	CbGpPWpGaD
Norfloxacin—TOP2A—Norethindrone—Hydrocortisone—psoriasis	0.000225	0.168	CbGdCrCtD
Norfloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000196	0.00993	CbGpPWpGaD
Norfloxacin—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000194	0.00982	CbGpPWpGaD
Norfloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000193	0.0098	CbGpPWpGaD
Norfloxacin—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000191	0.00969	CbGpPWpGaD
Norfloxacin—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000188	0.00952	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000187	0.0095	CbGpPWpGaD
Norfloxacin—TOP2A—Levonorgestrel—Hydrocortisone—psoriasis	0.000179	0.134	CbGdCrCtD
Norfloxacin—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000178	0.009	CbGpPWpGaD
Norfloxacin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000171	0.00868	CbGpPWpGaD
Norfloxacin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000165	0.00835	CbGpPWpGaD
Norfloxacin—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000161	0.00815	CbGpPWpGaD
Norfloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000159	0.00805	CbGpPWpGaD
Norfloxacin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000151	0.00767	CbGpPWpGaD
Norfloxacin—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000151	0.00764	CbGpPWpGaD
Norfloxacin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.00015	0.00758	CbGpPWpGaD
Norfloxacin—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000149	0.00757	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000147	0.00748	CbGpPWpGaD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000143	0.00727	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.00014	0.0071	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000138	0.007	CbGpPWpGaD
Norfloxacin—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000132	0.00671	CbGpPWpGaD
Norfloxacin—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000131	0.00662	CbGpPWpGaD
Norfloxacin—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.00013	0.0066	CbGpPWpGaD
Norfloxacin—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000128	0.0065	CbGpPWpGaD
Norfloxacin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000123	0.00621	CbGpPWpGaD
Norfloxacin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000121	0.00613	CbGpPWpGaD
Norfloxacin—TOP2A—Gastric Cancer Network 2—TP53—psoriasis	0.00012	0.0061	CbGpPWpGaD
Norfloxacin—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000114	0.00579	CbGpPWpGaD
Norfloxacin—SLC22A5—SLC-mediated transmembrane transport—CP—psoriasis	0.000113	0.00573	CbGpPWpGaD
Norfloxacin—Hyperhidrosis—Prednisolone—psoriasis	0.000107	0.00048	CcSEcCtD
Norfloxacin—Nausea—Hydroxyurea—psoriasis	0.000107	0.000478	CcSEcCtD
Norfloxacin—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000107	0.000478	CcSEcCtD
Norfloxacin—Pruritus—Mycophenolic acid—psoriasis	0.000106	0.000477	CcSEcCtD
Norfloxacin—Myalgia—Triamcinolone—psoriasis	0.000106	0.000476	CcSEcCtD
Norfloxacin—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000106	0.000475	CcSEcCtD
Norfloxacin—Decreased appetite—Cyclosporine—psoriasis	0.000106	0.000474	CcSEcCtD
Norfloxacin—Somnolence—Mycophenolate mofetil—psoriasis	0.000105	0.000473	CcSEcCtD
Norfloxacin—Drowsiness—Methotrexate—psoriasis	0.000105	0.000473	CcSEcCtD
Norfloxacin—Fatigue—Cyclosporine—psoriasis	0.000105	0.00047	CcSEcCtD
Norfloxacin—Hyperhidrosis—Hydrocortisone—psoriasis	0.000105	0.000469	CcSEcCtD
Norfloxacin—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000104	0.000469	CcSEcCtD
Norfloxacin—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000104	0.000469	CcSEcCtD
Norfloxacin—Constipation—Cyclosporine—psoriasis	0.000104	0.000467	CcSEcCtD
Norfloxacin—Dry mouth—Triamcinolone—psoriasis	0.000104	0.000466	CcSEcCtD
Norfloxacin—Renal failure—Methotrexate—psoriasis	0.000104	0.000465	CcSEcCtD
Norfloxacin—Angioedema—Dexamethasone—psoriasis	0.000103	0.000464	CcSEcCtD
Norfloxacin—Angioedema—Betamethasone—psoriasis	0.000103	0.000464	CcSEcCtD
Norfloxacin—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000103	0.000463	CcSEcCtD
Norfloxacin—Anorexia—Hydrocortisone—psoriasis	0.000103	0.000462	CcSEcCtD
Norfloxacin—Diarrhoea—Mycophenolic acid—psoriasis	0.000103	0.000461	CcSEcCtD
Norfloxacin—Stomatitis—Methotrexate—psoriasis	0.000103	0.000461	CcSEcCtD
Norfloxacin—Conjunctivitis—Methotrexate—psoriasis	0.000102	0.00046	CcSEcCtD
Norfloxacin—Anaphylactic shock—Triamcinolone—psoriasis	0.000102	0.000457	CcSEcCtD
Norfloxacin—Oedema—Triamcinolone—psoriasis	0.000102	0.000457	CcSEcCtD
Norfloxacin—Vertigo—Betamethasone—psoriasis	0.000102	0.000456	CcSEcCtD
Norfloxacin—Vertigo—Dexamethasone—psoriasis	0.000102	0.000456	CcSEcCtD
Norfloxacin—Constipation—Mycophenolate mofetil—psoriasis	0.000101	0.000455	CcSEcCtD
Norfloxacin—TOP2A—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000101	0.00511	CbGpPWpGaD
Norfloxacin—Haematuria—Methotrexate—psoriasis	0.0001	0.000451	CcSEcCtD
Norfloxacin—Feeling abnormal—Cyclosporine—psoriasis	0.0001	0.00045	CcSEcCtD
Norfloxacin—Insomnia—Prednisolone—psoriasis	0.0001	0.000449	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Cyclosporine—psoriasis	9.95e-05	0.000446	CcSEcCtD
Norfloxacin—Dizziness—Mycophenolic acid—psoriasis	9.94e-05	0.000446	CcSEcCtD
Norfloxacin—Paraesthesia—Prednisolone—psoriasis	9.94e-05	0.000446	CcSEcCtD
Norfloxacin—CYP2A6—NRF2 pathway—TGFA—psoriasis	9.89e-05	0.00501	CbGpPWpGaD
Norfloxacin—Erythema—Prednisone—psoriasis	9.86e-05	0.000442	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Hydrocortisone—psoriasis	9.85e-05	0.000442	CcSEcCtD
Norfloxacin—Hyperhidrosis—Triamcinolone—psoriasis	9.84e-05	0.000441	CcSEcCtD
Norfloxacin—Agranulocytosis—Methotrexate—psoriasis	9.84e-05	0.000441	CcSEcCtD
Norfloxacin—Convulsion—Dexamethasone—psoriasis	9.81e-05	0.00044	CcSEcCtD
Norfloxacin—Convulsion—Betamethasone—psoriasis	9.81e-05	0.00044	CcSEcCtD
Norfloxacin—Feeling abnormal—Mycophenolate mofetil—psoriasis	9.78e-05	0.000439	CcSEcCtD
Norfloxacin—Insomnia—Hydrocortisone—psoriasis	9.78e-05	0.000439	CcSEcCtD
Norfloxacin—Paraesthesia—Hydrocortisone—psoriasis	9.71e-05	0.000435	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	9.7e-05	0.000435	CcSEcCtD
Norfloxacin—Urticaria—Cyclosporine—psoriasis	9.66e-05	0.000433	CcSEcCtD
Norfloxacin—Myalgia—Dexamethasone—psoriasis	9.63e-05	0.000432	CcSEcCtD
Norfloxacin—Myalgia—Betamethasone—psoriasis	9.63e-05	0.000432	CcSEcCtD
Norfloxacin—Body temperature increased—Cyclosporine—psoriasis	9.62e-05	0.000431	CcSEcCtD
Norfloxacin—Abdominal pain—Cyclosporine—psoriasis	9.62e-05	0.000431	CcSEcCtD
Norfloxacin—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	9.61e-05	0.00487	CbGpPWpGaD
Norfloxacin—Anxiety—Betamethasone—psoriasis	9.6e-05	0.000431	CcSEcCtD
Norfloxacin—Anxiety—Dexamethasone—psoriasis	9.6e-05	0.000431	CcSEcCtD
Norfloxacin—Vomiting—Mycophenolic acid—psoriasis	9.56e-05	0.000429	CcSEcCtD
Norfloxacin—Dyspepsia—Hydrocortisone—psoriasis	9.52e-05	0.000427	CcSEcCtD
Norfloxacin—Rash—Mycophenolic acid—psoriasis	9.48e-05	0.000425	CcSEcCtD
Norfloxacin—Dermatitis—Mycophenolic acid—psoriasis	9.47e-05	0.000425	CcSEcCtD
Norfloxacin—Hepatitis—Methotrexate—psoriasis	9.46e-05	0.000424	CcSEcCtD
Norfloxacin—Urticaria—Mycophenolate mofetil—psoriasis	9.43e-05	0.000423	CcSEcCtD
Norfloxacin—Headache—Mycophenolic acid—psoriasis	9.42e-05	0.000423	CcSEcCtD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	9.4e-05	0.00477	CbGpPWpGaD
Norfloxacin—Decreased appetite—Hydrocortisone—psoriasis	9.4e-05	0.000422	CcSEcCtD
Norfloxacin—Body temperature increased—Mycophenolate mofetil—psoriasis	9.38e-05	0.000421	CcSEcCtD
Norfloxacin—Abdominal pain—Mycophenolate mofetil—psoriasis	9.38e-05	0.000421	CcSEcCtD
Norfloxacin—Fatigue—Hydrocortisone—psoriasis	9.32e-05	0.000418	CcSEcCtD
Norfloxacin—Vision blurred—Prednisone—psoriasis	9.29e-05	0.000417	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.27e-05	0.000416	CcSEcCtD
Norfloxacin—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	9.24e-05	0.00468	CbGpPWpGaD
Norfloxacin—Oedema—Dexamethasone—psoriasis	9.24e-05	0.000414	CcSEcCtD
Norfloxacin—Anaphylactic shock—Dexamethasone—psoriasis	9.24e-05	0.000414	CcSEcCtD
Norfloxacin—Anaphylactic shock—Betamethasone—psoriasis	9.24e-05	0.000414	CcSEcCtD
Norfloxacin—Oedema—Betamethasone—psoriasis	9.24e-05	0.000414	CcSEcCtD
Norfloxacin—Insomnia—Triamcinolone—psoriasis	9.21e-05	0.000413	CcSEcCtD
Norfloxacin—Paraesthesia—Triamcinolone—psoriasis	9.14e-05	0.00041	CcSEcCtD
Norfloxacin—Feeling abnormal—Prednisolone—psoriasis	9.12e-05	0.000409	CcSEcCtD
Norfloxacin—Visual impairment—Methotrexate—psoriasis	9.12e-05	0.000409	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—PTTG1—psoriasis	9.08e-05	0.0046	CbGpPWpGaD
Norfloxacin—Dyspnoea—Triamcinolone—psoriasis	9.08e-05	0.000407	CcSEcCtD
Norfloxacin—Agitation—Prednisone—psoriasis	9.06e-05	0.000406	CcSEcCtD
Norfloxacin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	9.05e-05	0.00458	CbGpPWpGaD
Norfloxacin—Thrombocytopenia—Betamethasone—psoriasis	9.04e-05	0.000406	CcSEcCtD
Norfloxacin—Thrombocytopenia—Dexamethasone—psoriasis	9.04e-05	0.000406	CcSEcCtD
Norfloxacin—Angioedema—Prednisone—psoriasis	9.01e-05	0.000404	CcSEcCtD
Norfloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9e-05	0.00456	CbGpPWpGaD
Norfloxacin—Hypersensitivity—Cyclosporine—psoriasis	8.96e-05	0.000402	CcSEcCtD
Norfloxacin—Dyspepsia—Triamcinolone—psoriasis	8.96e-05	0.000402	CcSEcCtD
Norfloxacin—Erythema multiforme—Methotrexate—psoriasis	8.95e-05	0.000401	CcSEcCtD
Norfloxacin—Nausea—Mycophenolic acid—psoriasis	8.93e-05	0.000401	CcSEcCtD
Norfloxacin—Hyperhidrosis—Betamethasone—psoriasis	8.93e-05	0.000401	CcSEcCtD
Norfloxacin—Hyperhidrosis—Dexamethasone—psoriasis	8.93e-05	0.000401	CcSEcCtD
Norfloxacin—Feeling abnormal—Hydrocortisone—psoriasis	8.91e-05	0.0004	CcSEcCtD
Norfloxacin—Vertigo—Prednisone—psoriasis	8.85e-05	0.000397	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Hydrocortisone—psoriasis	8.84e-05	0.000397	CcSEcCtD
Norfloxacin—Tinnitus—Methotrexate—psoriasis	8.82e-05	0.000396	CcSEcCtD
Norfloxacin—Anorexia—Betamethasone—psoriasis	8.8e-05	0.000395	CcSEcCtD
Norfloxacin—Anorexia—Dexamethasone—psoriasis	8.8e-05	0.000395	CcSEcCtD
Norfloxacin—Urticaria—Prednisolone—psoriasis	8.79e-05	0.000394	CcSEcCtD
Norfloxacin—Fatigue—Triamcinolone—psoriasis	8.78e-05	0.000394	CcSEcCtD
Norfloxacin—Hypersensitivity—Mycophenolate mofetil—psoriasis	8.74e-05	0.000392	CcSEcCtD
Norfloxacin—Asthenia—Cyclosporine—psoriasis	8.73e-05	0.000391	CcSEcCtD
Norfloxacin—Pruritus—Cyclosporine—psoriasis	8.61e-05	0.000386	CcSEcCtD
Norfloxacin—Urticaria—Hydrocortisone—psoriasis	8.59e-05	0.000385	CcSEcCtD
Norfloxacin—Body temperature increased—Hydrocortisone—psoriasis	8.55e-05	0.000383	CcSEcCtD
Norfloxacin—Abdominal pain—Hydrocortisone—psoriasis	8.55e-05	0.000383	CcSEcCtD
Norfloxacin—Convulsion—Prednisone—psoriasis	8.54e-05	0.000383	CcSEcCtD
Norfloxacin—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	8.54e-05	0.00433	CbGpPWpGaD
Norfloxacin—Asthenia—Mycophenolate mofetil—psoriasis	8.51e-05	0.000382	CcSEcCtD
Norfloxacin—Chills—Methotrexate—psoriasis	8.49e-05	0.000381	CcSEcCtD
Norfloxacin—CYP1A2—Biological oxidations—CYP2S1—psoriasis	8.44e-05	0.00428	CbGpPWpGaD
Norfloxacin—Musculoskeletal discomfort—Betamethasone—psoriasis	8.41e-05	0.000377	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.41e-05	0.000377	CcSEcCtD
Norfloxacin—Pruritus—Mycophenolate mofetil—psoriasis	8.4e-05	0.000377	CcSEcCtD
Norfloxacin—Myalgia—Prednisone—psoriasis	8.39e-05	0.000376	CcSEcCtD
Norfloxacin—Arthralgia—Prednisone—psoriasis	8.39e-05	0.000376	CcSEcCtD
Norfloxacin—Feeling abnormal—Triamcinolone—psoriasis	8.39e-05	0.000376	CcSEcCtD
Norfloxacin—Anxiety—Prednisone—psoriasis	8.36e-05	0.000375	CcSEcCtD
Norfloxacin—Insomnia—Dexamethasone—psoriasis	8.35e-05	0.000375	CcSEcCtD
Norfloxacin—Insomnia—Betamethasone—psoriasis	8.35e-05	0.000375	CcSEcCtD
Norfloxacin—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	8.32e-05	0.00422	CbGpPWpGaD
Norfloxacin—Diarrhoea—Cyclosporine—psoriasis	8.32e-05	0.000373	CcSEcCtD
Norfloxacin—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	8.31e-05	0.00421	CbGpPWpGaD
Norfloxacin—Paraesthesia—Betamethasone—psoriasis	8.29e-05	0.000372	CcSEcCtD
Norfloxacin—Paraesthesia—Dexamethasone—psoriasis	8.29e-05	0.000372	CcSEcCtD
Norfloxacin—Erythema—Methotrexate—psoriasis	8.24e-05	0.000369	CcSEcCtD
Norfloxacin—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	8.18e-05	0.00415	CbGpPWpGaD
Norfloxacin—Hypersensitivity—Prednisolone—psoriasis	8.16e-05	0.000366	CcSEcCtD
Norfloxacin—Dyspepsia—Dexamethasone—psoriasis	8.13e-05	0.000365	CcSEcCtD
Norfloxacin—Dyspepsia—Betamethasone—psoriasis	8.13e-05	0.000365	CcSEcCtD
Norfloxacin—Diarrhoea—Mycophenolate mofetil—psoriasis	8.12e-05	0.000364	CcSEcCtD
Norfloxacin—TOP2A—Cell Cycle—PTTG1—psoriasis	8.12e-05	0.00411	CbGpPWpGaD
Norfloxacin—Urticaria—Triamcinolone—psoriasis	8.09e-05	0.000363	CcSEcCtD
Norfloxacin—Dysgeusia—Methotrexate—psoriasis	8.07e-05	0.000362	CcSEcCtD
Norfloxacin—Body temperature increased—Triamcinolone—psoriasis	8.05e-05	0.000361	CcSEcCtD
Norfloxacin—Dizziness—Cyclosporine—psoriasis	8.04e-05	0.000361	CcSEcCtD
Norfloxacin—Oedema—Prednisone—psoriasis	8.04e-05	0.000361	CcSEcCtD
Norfloxacin—Anaphylactic shock—Prednisone—psoriasis	8.04e-05	0.000361	CcSEcCtD
Norfloxacin—Decreased appetite—Dexamethasone—psoriasis	8.03e-05	0.00036	CcSEcCtD
Norfloxacin—Decreased appetite—Betamethasone—psoriasis	8.03e-05	0.00036	CcSEcCtD
Norfloxacin—Back pain—Methotrexate—psoriasis	7.97e-05	0.000357	CcSEcCtD
Norfloxacin—Hypersensitivity—Hydrocortisone—psoriasis	7.96e-05	0.000357	CcSEcCtD
Norfloxacin—Fatigue—Dexamethasone—psoriasis	7.96e-05	0.000357	CcSEcCtD
Norfloxacin—Fatigue—Betamethasone—psoriasis	7.96e-05	0.000357	CcSEcCtD
Norfloxacin—Dizziness—Mycophenolate mofetil—psoriasis	7.85e-05	0.000352	CcSEcCtD
Norfloxacin—Hyperhidrosis—Prednisone—psoriasis	7.78e-05	0.000349	CcSEcCtD
Norfloxacin—Vision blurred—Methotrexate—psoriasis	7.76e-05	0.000348	CcSEcCtD
Norfloxacin—Asthenia—Hydrocortisone—psoriasis	7.76e-05	0.000348	CcSEcCtD
Norfloxacin—Vomiting—Cyclosporine—psoriasis	7.73e-05	0.000347	CcSEcCtD
Norfloxacin—Rash—Cyclosporine—psoriasis	7.67e-05	0.000344	CcSEcCtD
Norfloxacin—Anorexia—Prednisone—psoriasis	7.67e-05	0.000344	CcSEcCtD
Norfloxacin—Dermatitis—Cyclosporine—psoriasis	7.66e-05	0.000344	CcSEcCtD
Norfloxacin—Pruritus—Hydrocortisone—psoriasis	7.65e-05	0.000343	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	7.64e-05	0.00387	CbGpPWpGaD
Norfloxacin—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	7.63e-05	0.00387	CbGpPWpGaD
Norfloxacin—Headache—Cyclosporine—psoriasis	7.62e-05	0.000342	CcSEcCtD
Norfloxacin—Feeling abnormal—Dexamethasone—psoriasis	7.61e-05	0.000341	CcSEcCtD
Norfloxacin—Feeling abnormal—Betamethasone—psoriasis	7.61e-05	0.000341	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Dexamethasone—psoriasis	7.55e-05	0.000339	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Betamethasone—psoriasis	7.55e-05	0.000339	CcSEcCtD
Norfloxacin—Vomiting—Mycophenolate mofetil—psoriasis	7.54e-05	0.000338	CcSEcCtD
Norfloxacin—Hypersensitivity—Triamcinolone—psoriasis	7.5e-05	0.000336	CcSEcCtD
Norfloxacin—Rash—Mycophenolate mofetil—psoriasis	7.48e-05	0.000336	CcSEcCtD
Norfloxacin—Dermatitis—Mycophenolate mofetil—psoriasis	7.47e-05	0.000335	CcSEcCtD
Norfloxacin—Headache—Mycophenolate mofetil—psoriasis	7.43e-05	0.000333	CcSEcCtD
Norfloxacin—CYP1A1—Oxidative Stress—NFKB1—psoriasis	7.43e-05	0.00376	CbGpPWpGaD
Norfloxacin—Vertigo—Methotrexate—psoriasis	7.4e-05	0.000332	CcSEcCtD
Norfloxacin—Diarrhoea—Hydrocortisone—psoriasis	7.4e-05	0.000332	CcSEcCtD
Norfloxacin—Leukopenia—Methotrexate—psoriasis	7.37e-05	0.000331	CcSEcCtD
Norfloxacin—Urticaria—Betamethasone—psoriasis	7.34e-05	0.000329	CcSEcCtD
Norfloxacin—Urticaria—Dexamethasone—psoriasis	7.34e-05	0.000329	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Prednisone—psoriasis	7.33e-05	0.000329	CcSEcCtD
Norfloxacin—Dizziness—Prednisolone—psoriasis	7.32e-05	0.000328	CcSEcCtD
Norfloxacin—Asthenia—Triamcinolone—psoriasis	7.3e-05	0.000328	CcSEcCtD
Norfloxacin—Body temperature increased—Betamethasone—psoriasis	7.3e-05	0.000328	CcSEcCtD
Norfloxacin—Body temperature increased—Dexamethasone—psoriasis	7.3e-05	0.000328	CcSEcCtD
Norfloxacin—Abdominal pain—Dexamethasone—psoriasis	7.3e-05	0.000328	CcSEcCtD
Norfloxacin—Abdominal pain—Betamethasone—psoriasis	7.3e-05	0.000328	CcSEcCtD
Norfloxacin—CYP1A2—Tryptophan metabolism—CAT—psoriasis	7.28e-05	0.00369	CbGpPWpGaD
Norfloxacin—Insomnia—Prednisone—psoriasis	7.27e-05	0.000326	CcSEcCtD
Norfloxacin—Nausea—Cyclosporine—psoriasis	7.23e-05	0.000324	CcSEcCtD
Norfloxacin—Paraesthesia—Prednisone—psoriasis	7.22e-05	0.000324	CcSEcCtD
Norfloxacin—Pruritus—Triamcinolone—psoriasis	7.2e-05	0.000323	CcSEcCtD
Norfloxacin—Dizziness—Hydrocortisone—psoriasis	7.15e-05	0.000321	CcSEcCtD
Norfloxacin—Convulsion—Methotrexate—psoriasis	7.14e-05	0.00032	CcSEcCtD
Norfloxacin—Dyspepsia—Prednisone—psoriasis	7.08e-05	0.000318	CcSEcCtD
Norfloxacin—Nausea—Mycophenolate mofetil—psoriasis	7.05e-05	0.000316	CcSEcCtD
Norfloxacin—Arthralgia—Methotrexate—psoriasis	7.01e-05	0.000315	CcSEcCtD
Norfloxacin—Myalgia—Methotrexate—psoriasis	7.01e-05	0.000315	CcSEcCtD
Norfloxacin—Chest pain—Methotrexate—psoriasis	7.01e-05	0.000315	CcSEcCtD
Norfloxacin—Decreased appetite—Prednisone—psoriasis	6.99e-05	0.000314	CcSEcCtD
Norfloxacin—Rash—Prednisolone—psoriasis	6.98e-05	0.000313	CcSEcCtD
Norfloxacin—Dermatitis—Prednisolone—psoriasis	6.97e-05	0.000313	CcSEcCtD
Norfloxacin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.95e-05	0.00352	CbGpPWpGaD
Norfloxacin—Fatigue—Prednisone—psoriasis	6.93e-05	0.000311	CcSEcCtD
Norfloxacin—Headache—Prednisolone—psoriasis	6.93e-05	0.000311	CcSEcCtD
Norfloxacin—Constipation—Prednisone—psoriasis	6.88e-05	0.000309	CcSEcCtD
Norfloxacin—Vomiting—Hydrocortisone—psoriasis	6.87e-05	0.000308	CcSEcCtD
Norfloxacin—Rash—Hydrocortisone—psoriasis	6.82e-05	0.000306	CcSEcCtD
Norfloxacin—Dermatitis—Hydrocortisone—psoriasis	6.81e-05	0.000305	CcSEcCtD
Norfloxacin—Confusional state—Methotrexate—psoriasis	6.78e-05	0.000304	CcSEcCtD
Norfloxacin—Headache—Hydrocortisone—psoriasis	6.77e-05	0.000304	CcSEcCtD
Norfloxacin—Dizziness—Triamcinolone—psoriasis	6.73e-05	0.000302	CcSEcCtD
Norfloxacin—Anaphylactic shock—Methotrexate—psoriasis	6.72e-05	0.000302	CcSEcCtD
Norfloxacin—Feeling abnormal—Prednisone—psoriasis	6.63e-05	0.000297	CcSEcCtD
Norfloxacin—Asthenia—Dexamethasone—psoriasis	6.63e-05	0.000297	CcSEcCtD
Norfloxacin—Asthenia—Betamethasone—psoriasis	6.63e-05	0.000297	CcSEcCtD
Norfloxacin—TOP2A—Circadian rythm related genes—LEP—psoriasis	6.61e-05	0.00335	CbGpPWpGaD
Norfloxacin—Thrombocytopenia—Methotrexate—psoriasis	6.58e-05	0.000295	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Prednisone—psoriasis	6.58e-05	0.000295	CcSEcCtD
Norfloxacin—Nausea—Prednisolone—psoriasis	6.57e-05	0.000295	CcSEcCtD
Norfloxacin—Pruritus—Betamethasone—psoriasis	6.53e-05	0.000293	CcSEcCtD
Norfloxacin—Pruritus—Dexamethasone—psoriasis	6.53e-05	0.000293	CcSEcCtD
Norfloxacin—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.51e-05	0.0033	CbGpPWpGaD
Norfloxacin—Hyperhidrosis—Methotrexate—psoriasis	6.5e-05	0.000292	CcSEcCtD
Norfloxacin—Vomiting—Triamcinolone—psoriasis	6.47e-05	0.00029	CcSEcCtD
Norfloxacin—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.42e-05	0.00326	CbGpPWpGaD
Norfloxacin—Nausea—Hydrocortisone—psoriasis	6.42e-05	0.000288	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	6.42e-05	0.00325	CbGpPWpGaD
Norfloxacin—Rash—Triamcinolone—psoriasis	6.42e-05	0.000288	CcSEcCtD
Norfloxacin—Dermatitis—Triamcinolone—psoriasis	6.41e-05	0.000288	CcSEcCtD
Norfloxacin—Anorexia—Methotrexate—psoriasis	6.41e-05	0.000287	CcSEcCtD
Norfloxacin—Urticaria—Prednisone—psoriasis	6.39e-05	0.000287	CcSEcCtD
Norfloxacin—Headache—Triamcinolone—psoriasis	6.38e-05	0.000286	CcSEcCtD
Norfloxacin—Abdominal pain—Prednisone—psoriasis	6.36e-05	0.000285	CcSEcCtD
Norfloxacin—Body temperature increased—Prednisone—psoriasis	6.36e-05	0.000285	CcSEcCtD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.34e-05	0.00321	CbGpPWpGaD
Norfloxacin—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	6.33e-05	0.00321	CbGpPWpGaD
Norfloxacin—Diarrhoea—Dexamethasone—psoriasis	6.32e-05	0.000283	CcSEcCtD
Norfloxacin—Diarrhoea—Betamethasone—psoriasis	6.32e-05	0.000283	CcSEcCtD
Norfloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.28e-05	0.00318	CbGpPWpGaD
Norfloxacin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	6.23e-05	0.00316	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—NOS2—psoriasis	6.16e-05	0.00312	CbGpPWpGaD
Norfloxacin—Musculoskeletal discomfort—Methotrexate—psoriasis	6.12e-05	0.000275	CcSEcCtD
Norfloxacin—Dizziness—Betamethasone—psoriasis	6.11e-05	0.000274	CcSEcCtD
Norfloxacin—Dizziness—Dexamethasone—psoriasis	6.11e-05	0.000274	CcSEcCtD
Norfloxacin—Insomnia—Methotrexate—psoriasis	6.08e-05	0.000273	CcSEcCtD
Norfloxacin—Nausea—Triamcinolone—psoriasis	6.05e-05	0.000271	CcSEcCtD
Norfloxacin—Paraesthesia—Methotrexate—psoriasis	6.04e-05	0.000271	CcSEcCtD
Norfloxacin—Dyspnoea—Methotrexate—psoriasis	5.99e-05	0.000269	CcSEcCtD
Norfloxacin—Somnolence—Methotrexate—psoriasis	5.98e-05	0.000268	CcSEcCtD
Norfloxacin—Hypersensitivity—Prednisone—psoriasis	5.93e-05	0.000266	CcSEcCtD
Norfloxacin—Dyspepsia—Methotrexate—psoriasis	5.92e-05	0.000265	CcSEcCtD
Norfloxacin—Vomiting—Dexamethasone—psoriasis	5.87e-05	0.000263	CcSEcCtD
Norfloxacin—Vomiting—Betamethasone—psoriasis	5.87e-05	0.000263	CcSEcCtD
Norfloxacin—Decreased appetite—Methotrexate—psoriasis	5.84e-05	0.000262	CcSEcCtD
Norfloxacin—Rash—Betamethasone—psoriasis	5.82e-05	0.000261	CcSEcCtD
Norfloxacin—Rash—Dexamethasone—psoriasis	5.82e-05	0.000261	CcSEcCtD
Norfloxacin—Dermatitis—Betamethasone—psoriasis	5.82e-05	0.000261	CcSEcCtD
Norfloxacin—Dermatitis—Dexamethasone—psoriasis	5.82e-05	0.000261	CcSEcCtD
Norfloxacin—Fatigue—Methotrexate—psoriasis	5.8e-05	0.00026	CcSEcCtD
Norfloxacin—Headache—Betamethasone—psoriasis	5.79e-05	0.00026	CcSEcCtD
Norfloxacin—Headache—Dexamethasone—psoriasis	5.79e-05	0.00026	CcSEcCtD
Norfloxacin—Asthenia—Prednisone—psoriasis	5.77e-05	0.000259	CcSEcCtD
Norfloxacin—TOP2A—Circadian rythm related genes—PPARG—psoriasis	5.76e-05	0.00292	CbGpPWpGaD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—CP—psoriasis	5.75e-05	0.00291	CbGpPWpGaD
Norfloxacin—Pruritus—Prednisone—psoriasis	5.69e-05	0.000255	CcSEcCtD
Norfloxacin—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.62e-05	0.00285	CbGpPWpGaD
Norfloxacin—Feeling abnormal—Methotrexate—psoriasis	5.54e-05	0.000248	CcSEcCtD
Norfloxacin—Diarrhoea—Prednisone—psoriasis	5.5e-05	0.000247	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Methotrexate—psoriasis	5.5e-05	0.000247	CcSEcCtD
Norfloxacin—Nausea—Dexamethasone—psoriasis	5.49e-05	0.000246	CcSEcCtD
Norfloxacin—Nausea—Betamethasone—psoriasis	5.49e-05	0.000246	CcSEcCtD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—CARM1—psoriasis	5.48e-05	0.00278	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.48e-05	0.00278	CbGpPWpGaD
Norfloxacin—Urticaria—Methotrexate—psoriasis	5.34e-05	0.00024	CcSEcCtD
Norfloxacin—Dizziness—Prednisone—psoriasis	5.32e-05	0.000239	CcSEcCtD
Norfloxacin—Abdominal pain—Methotrexate—psoriasis	5.31e-05	0.000238	CcSEcCtD
Norfloxacin—Body temperature increased—Methotrexate—psoriasis	5.31e-05	0.000238	CcSEcCtD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.28e-05	0.00267	CbGpPWpGaD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—psoriasis	5.27e-05	0.00267	CbGpPWpGaD
Norfloxacin—Vomiting—Prednisone—psoriasis	5.11e-05	0.000229	CcSEcCtD
Norfloxacin—Rash—Prednisone—psoriasis	5.07e-05	0.000227	CcSEcCtD
Norfloxacin—Dermatitis—Prednisone—psoriasis	5.07e-05	0.000227	CcSEcCtD
Norfloxacin—Headache—Prednisone—psoriasis	5.04e-05	0.000226	CcSEcCtD
Norfloxacin—Hypersensitivity—Methotrexate—psoriasis	4.95e-05	0.000222	CcSEcCtD
Norfloxacin—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	4.87e-05	0.00247	CbGpPWpGaD
Norfloxacin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.84e-05	0.00245	CbGpPWpGaD
Norfloxacin—Asthenia—Methotrexate—psoriasis	4.82e-05	0.000216	CcSEcCtD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.79e-05	0.00243	CbGpPWpGaD
Norfloxacin—Nausea—Prednisone—psoriasis	4.78e-05	0.000214	CcSEcCtD
Norfloxacin—Pruritus—Methotrexate—psoriasis	4.76e-05	0.000213	CcSEcCtD
Norfloxacin—Diarrhoea—Methotrexate—psoriasis	4.6e-05	0.000206	CcSEcCtD
Norfloxacin—Dizziness—Methotrexate—psoriasis	4.45e-05	0.000199	CcSEcCtD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	4.34e-05	0.0022	CbGpPWpGaD
Norfloxacin—Vomiting—Methotrexate—psoriasis	4.27e-05	0.000192	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	4.26e-05	0.00216	CbGpPWpGaD
Norfloxacin—Rash—Methotrexate—psoriasis	4.24e-05	0.00019	CcSEcCtD
Norfloxacin—Dermatitis—Methotrexate—psoriasis	4.23e-05	0.00019	CcSEcCtD
Norfloxacin—Headache—Methotrexate—psoriasis	4.21e-05	0.000189	CcSEcCtD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	4.14e-05	0.0021	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.1e-05	0.00208	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.1e-05	0.00208	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.1e-05	0.00208	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—JUN—psoriasis	4.09e-05	0.00207	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.04e-05	0.00205	CbGpPWpGaD
Norfloxacin—Nausea—Methotrexate—psoriasis	3.99e-05	0.000179	CcSEcCtD
Norfloxacin—CYP3A7—Metabolism—NDUFA5—psoriasis	3.9e-05	0.00198	CbGpPWpGaD
Norfloxacin—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	3.85e-05	0.00195	CbGpPWpGaD
Norfloxacin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	3.77e-05	0.00191	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.72e-05	0.00188	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—PCNA—psoriasis	3.7e-05	0.00188	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—NDUFA5—psoriasis	3.57e-05	0.00181	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.5e-05	0.00177	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.36e-05	0.00171	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CYP2S1—psoriasis	3.31e-05	0.00168	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—PCNA—psoriasis	3.31e-05	0.00168	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.19e-05	0.00162	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.05e-05	0.00155	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CYP2S1—psoriasis	3.04e-05	0.00154	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—NDUFA5—psoriasis	2.82e-05	0.00143	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.81e-05	0.00142	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—TP53—psoriasis	2.7e-05	0.00137	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—NDUFA5—psoriasis	2.66e-05	0.00135	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.62e-05	0.00133	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.62e-05	0.00133	CbGpPWpGaD
Norfloxacin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	2.59e-05	0.00132	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.48e-05	0.00126	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—IL6—psoriasis	2.47e-05	0.00125	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CYP2S1—psoriasis	2.4e-05	0.00121	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—CYP2S1—psoriasis	2.26e-05	0.00115	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—NDUFA5—psoriasis	1.7e-05	0.00086	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CARM1—psoriasis	1.62e-05	0.00082	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.58e-05	0.000802	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CARM1—psoriasis	1.48e-05	0.000752	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—CYP2S1—psoriasis	1.44e-05	0.000731	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—NDUFA5—psoriasis	1.31e-05	0.000664	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—TP53—psoriasis	1.22e-05	0.000617	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.19e-05	0.000601	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CARM1—psoriasis	1.17e-05	0.000593	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—CYP2S1—psoriasis	1.11e-05	0.000565	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—CARM1—psoriasis	1.11e-05	0.00056	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.03e-05	0.000524	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CAT—psoriasis	9.96e-06	0.000505	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CAT—psoriasis	9.13e-06	0.000463	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—APOE—psoriasis	7.74e-06	0.000392	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.56e-06	0.000383	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CAT—psoriasis	7.2e-06	0.000365	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—APOE—psoriasis	7.09e-06	0.000359	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—CARM1—psoriasis	7.05e-06	0.000357	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—CAT—psoriasis	6.8e-06	0.000345	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—PPARG—psoriasis	6.74e-06	0.000341	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.59e-06	0.000334	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—PPARG—psoriasis	6.18e-06	0.000313	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—APOE—psoriasis	5.59e-06	0.000283	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—CARM1—psoriasis	5.44e-06	0.000276	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—APOE—psoriasis	5.28e-06	0.000268	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—PPARG—psoriasis	4.87e-06	0.000247	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—PPARG—psoriasis	4.6e-06	0.000233	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—CAT—psoriasis	4.34e-06	0.00022	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—APOE—psoriasis	3.37e-06	0.000171	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—CAT—psoriasis	3.35e-06	0.00017	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—PPARG—psoriasis	2.93e-06	0.000149	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—APOE—psoriasis	2.6e-06	0.000132	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—PPARG—psoriasis	2.26e-06	0.000115	CbGpPWpGaD
